Induction of laryngeal cancer cell death by Ent-11-hydroxy-15-oxo-kaur-16-en-19-oic acid. 2010

Alexander C Vlantis, and Chun Shan Lo, and George G Chen, and Nian Ci Liang, and Vivian W Y Lui, and Kefeng Wu, and Yi Feng Deng, and Xianling Gong, and Yingnian Lu, and Michael C F Tong, and C Andrew van Hasselt
Department of Otorhinolaryngology-Head and Neck Surgery, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong. lexvlantis@cuhk.edu.hk

BACKGROUND Ent-11-hydroxy-15-oxo-kaur-16-en-19-oic acid (5F) is known to exhibit antitumor activity, but its mechanism is not completely understood. 5F has not been tested in laryngeal cancer. METHODS Two laryngeal cancer cell lines were treated with 5F. Cell death was analyzed by MTT [3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyltetrazolium bromide] and Annexin V assay. Nuclear factor kappa beta (NF-κB)- and apoptosis-related molecules were examined. RESULTS 5F induced laryngeal cancer cell death in a dose-dependent manner. The Annexin V assay and the measurement of cleavage of procaspase-3 and poly(ADP-ribose) polymerase demonstrated that the 5F-induced cell death was mainly apoptotic. 5F slightly reduced the basal level of NF-κB, but significantly suppressed the inducible NF-κB by reducing its transcriptional activity, protecting its inhibitory subunit IκBα from degradation, and suppressing its level in the nucleus. 5F also inhibited pro-proliferative and anti-apoptotic molecules but promoted pro-apoptotic Bax. CONCLUSIONS 5F induces apoptosis of laryngeal cancer cells by inhibiting NF-κB activation/induction, suppressing pro-proliferative and anti-apoptotic molecules, and promoting pro-apoptotic Bax.

UI MeSH Term Description Entries
D007822 Laryngeal Neoplasms Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS. Cancer of Larynx,Laryngeal Cancer,Larynx Neoplasms,Cancer of the Larynx,Larynx Cancer,Neoplasms, Laryngeal,Cancer, Laryngeal,Cancer, Larynx,Cancers, Laryngeal,Cancers, Larynx,Laryngeal Cancers,Laryngeal Neoplasm,Larynx Cancers,Larynx Neoplasm,Neoplasm, Laryngeal,Neoplasm, Larynx,Neoplasms, Larynx
D008869 Microtubule-Associated Proteins High molecular weight proteins found in the MICROTUBULES of the cytoskeletal system. Under certain conditions they are required for TUBULIN assembly into the microtubules and stabilize the assembled microtubules. Ensconsin,Epithelial MAP, 115 kDa,Epithelial Microtubule-Associate Protein, 115 kDa,MAP4,Microtubule Associated Protein,Microtubule Associated Protein 4,Microtubule Associated Protein 7,Microtubule-Associated Protein,Microtubule-Associated Protein 7,E-MAP-115,MAP1 Microtubule-Associated Protein,MAP2 Microtubule-Associated Protein,MAP3 Microtubule-Associated Protein,Microtubule Associated Proteins,Microtubule-Associated Protein 1,Microtubule-Associated Protein 2,Microtubule-Associated Protein 3,7, Microtubule-Associated Protein,Associated Protein, Microtubule,E MAP 115,Epithelial Microtubule Associate Protein, 115 kDa,MAP1 Microtubule Associated Protein,MAP2 Microtubule Associated Protein,MAP3 Microtubule Associated Protein,Microtubule Associated Protein 1,Microtubule Associated Protein 2,Microtubule Associated Protein 3,Microtubule-Associated Protein, MAP1,Microtubule-Associated Protein, MAP2,Microtubule-Associated Protein, MAP3,Protein 7, Microtubule-Associated,Protein, Microtubule Associated,Protein, Microtubule-Associated
D011065 Poly(ADP-ribose) Polymerases Enzymes that catalyze the transfer of multiple ADP-RIBOSE groups from nicotinamide-adenine dinucleotide (NAD) onto protein targets, thus building up a linear or branched homopolymer of repeating ADP-ribose units i.e., POLY ADENOSINE DIPHOSPHATE RIBOSE. ADP-Ribosyltransferase (Polymerizing),Poly ADP Ribose Polymerase,Poly(ADP-Ribose) Synthase,Poly(ADP-ribose) Polymerase,PARP Polymerase,Poly ADP Ribose Transferase,Poly ADP-Ribose Synthase,Poly(ADP-Ribose) Transferase,Poly(ADPR) Polymerase,Poly(ADPribose) Polymerase,Poly ADP Ribose Synthase,Polymerase, PARP,Synthase, Poly ADP-Ribose
D004224 Diterpenes Twenty-carbon compounds derived from MEVALONIC ACID or deoxyxylulose phosphate. Diterpene,Diterpenes, Cembrane,Diterpenes, Labdane,Diterpenoid,Labdane Diterpene,Norditerpene,Norditerpenes,Norditerpenoid,Cembranes,Diterpenoids,Labdanes,Norditerpenoids,Cembrane Diterpenes,Diterpene, Labdane,Labdane Diterpenes
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004365 Drugs, Chinese Herbal Chinese herbal or plant extracts which are used as drugs to treat diseases or promote general well-being. The concept does not include synthesized compounds manufactured in China. Chinese Herbal Drugs,Plant Extracts, Chinese,Chinese Drugs, Plant,Chinese Plant Extracts,Extracts, Chinese Plant,Herbal Drugs, Chinese
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077022 Survivin An apoptosis inhibitory protein that contains a single baculoviral IAP repeat (BIR) domain. It associates with MICROTUBULES and functions to regulate cell proliferation as a component of the chromosome passage protein complex (CPC), performing essential roles for localization of the complex, chromosome alignment, segregation during MITOSIS and CYTOKINESIS, and assembly of the MITOTIC SPINDLE. It is expressed by fetal kidney and liver cells and highly expressed in ADENOCARCINOMA and high-grade LYMPHOMA. BIRC5 Protein,Baculoviral IAP Repeat-containing Protein 5,Baculoviral IAP Repeat containing Protein 5
D014158 Transcription, Genetic The biosynthesis of RNA carried out on a template of DNA. The biosynthesis of DNA from an RNA template is called REVERSE TRANSCRIPTION. Genetic Transcription
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha

Related Publications

Alexander C Vlantis, and Chun Shan Lo, and George G Chen, and Nian Ci Liang, and Vivian W Y Lui, and Kefeng Wu, and Yi Feng Deng, and Xianling Gong, and Yingnian Lu, and Michael C F Tong, and C Andrew van Hasselt
May 2010, Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica,
Alexander C Vlantis, and Chun Shan Lo, and George G Chen, and Nian Ci Liang, and Vivian W Y Lui, and Kefeng Wu, and Yi Feng Deng, and Xianling Gong, and Yingnian Lu, and Michael C F Tong, and C Andrew van Hasselt
December 2012, Current drug targets,
Alexander C Vlantis, and Chun Shan Lo, and George G Chen, and Nian Ci Liang, and Vivian W Y Lui, and Kefeng Wu, and Yi Feng Deng, and Xianling Gong, and Yingnian Lu, and Michael C F Tong, and C Andrew van Hasselt
December 2017, Oncology letters,
Alexander C Vlantis, and Chun Shan Lo, and George G Chen, and Nian Ci Liang, and Vivian W Y Lui, and Kefeng Wu, and Yi Feng Deng, and Xianling Gong, and Yingnian Lu, and Michael C F Tong, and C Andrew van Hasselt
August 2011, Nan fang yi ke da xue xue bao = Journal of Southern Medical University,
Alexander C Vlantis, and Chun Shan Lo, and George G Chen, and Nian Ci Liang, and Vivian W Y Lui, and Kefeng Wu, and Yi Feng Deng, and Xianling Gong, and Yingnian Lu, and Michael C F Tong, and C Andrew van Hasselt
December 2005, Apoptosis : an international journal on programmed cell death,
Alexander C Vlantis, and Chun Shan Lo, and George G Chen, and Nian Ci Liang, and Vivian W Y Lui, and Kefeng Wu, and Yi Feng Deng, and Xianling Gong, and Yingnian Lu, and Michael C F Tong, and C Andrew van Hasselt
June 2012, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu,
Alexander C Vlantis, and Chun Shan Lo, and George G Chen, and Nian Ci Liang, and Vivian W Y Lui, and Kefeng Wu, and Yi Feng Deng, and Xianling Gong, and Yingnian Lu, and Michael C F Tong, and C Andrew van Hasselt
June 2013, Oncology reports,
Alexander C Vlantis, and Chun Shan Lo, and George G Chen, and Nian Ci Liang, and Vivian W Y Lui, and Kefeng Wu, and Yi Feng Deng, and Xianling Gong, and Yingnian Lu, and Michael C F Tong, and C Andrew van Hasselt
June 2010, Natural product research,
Alexander C Vlantis, and Chun Shan Lo, and George G Chen, and Nian Ci Liang, and Vivian W Y Lui, and Kefeng Wu, and Yi Feng Deng, and Xianling Gong, and Yingnian Lu, and Michael C F Tong, and C Andrew van Hasselt
December 2012, Investigational new drugs,
Alexander C Vlantis, and Chun Shan Lo, and George G Chen, and Nian Ci Liang, and Vivian W Y Lui, and Kefeng Wu, and Yi Feng Deng, and Xianling Gong, and Yingnian Lu, and Michael C F Tong, and C Andrew van Hasselt
January 2013, International journal of nanomedicine,
Copied contents to your clipboard!